Clinical Trial

Assessing the Global Burden of IgA Nephropathy (IgAN) in Patients Receiving Hemodialysis: A Real-World Study Using DOPPS Data

Completed
View on ClinicalTrials.gov →
Summary
This study leverages the global Dialysis Outcomes and Practice Patterns Study (DOPPS) database to generate real-world evidence on the burden of IgAN in patients who progress to kidney failure and require maintenance hemodialysis (HD). We will first aim to understand prevalence of IgAN in a global cohort of in-center HD patients. The second and third objectives aim to quantify the patient burden of IgAN using a two-step approach: first, a detailed single-arm evaluation of outcomes within the IgAN population; second, a matched comparison to the broader HD population.
Trial Details
NCT Number NCT07607002
Lead Sponsor Arbor Research Collaborative for Health
Conditions IgAN - IgA Nephropathy
Enrollment 70,000 participants
Start Date 1996-01-01
Primary Completion 2023-12-31 (estimated)
Study Completion 2023-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-26